JP2014513731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513731A5 JP2014513731A5 JP2014511560A JP2014511560A JP2014513731A5 JP 2014513731 A5 JP2014513731 A5 JP 2014513731A5 JP 2014511560 A JP2014511560 A JP 2014511560A JP 2014511560 A JP2014511560 A JP 2014511560A JP 2014513731 A5 JP2014513731 A5 JP 2014513731A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- formula
- salt
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 64
- -1 C 1 -C 3 alkyl Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000000651 prodrug Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 17
- 239000002207 metabolite Substances 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 7
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 7
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 7
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims description 6
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 201000007455 central nervous system cancer Diseases 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- GRWPTSXPZYCYOM-UHFFFAOYSA-N 2-(dimethylamino)acetaldehyde Chemical compound CN(C)CC=O GRWPTSXPZYCYOM-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 238000007239 Wittig reaction Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003377 acid catalyst Substances 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/074165 WO2012155339A1 (zh) | 2011-05-17 | 2011-05-17 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| CNPCT/CN2011/074165 | 2011-05-17 | ||
| PCT/US2012/038458 WO2012158979A1 (en) | 2011-05-17 | 2012-05-17 | Quinazoline-7-ether compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014513731A JP2014513731A (ja) | 2014-06-05 |
| JP2014513731A5 true JP2014513731A5 (enExample) | 2015-07-09 |
Family
ID=47176142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511560A Pending JP2014513731A (ja) | 2011-05-17 | 2012-05-17 | キナゾリン−７−エーテル化合物および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9187459B2 (enExample) |
| EP (1) | EP2709999A4 (enExample) |
| JP (1) | JP2014513731A (enExample) |
| CN (1) | CN102918029B (enExample) |
| CA (1) | CA2873710A1 (enExample) |
| TW (2) | TWI448461B (enExample) |
| WO (2) | WO2012155339A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102382106A (zh) | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| SG10201601711SA (en) | 2011-03-04 | 2016-04-28 | Newgen Therapeutics Inc | Alkyne Substituted Quinazoline Compound And Methods Of Use |
| CN102918029B (zh) * | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| US9556191B2 (en) | 2013-04-28 | 2017-01-31 | Sunshine Lake Pharma Co., Ltd. | Aminoquinazoline derivatives and their salts and methods of use thereof |
| ES2784664T3 (es) * | 2013-07-18 | 2020-09-29 | Shanghai Fochon Pharmaceutical Co Ltd | Derivados de quinazolina, composiciones de los mismos y uso como productos farmacéuticos. |
| US10273227B2 (en) * | 2017-04-27 | 2019-04-30 | Astrazeneca Ab | C5-anilinoquinazoline compounds and their use in treating cancer |
| CN108947986A (zh) * | 2018-06-27 | 2018-12-07 | 苏州市贝克生物科技有限公司 | 阿法替尼降解杂质的合成方法 |
| US12435046B2 (en) | 2019-08-15 | 2025-10-07 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| WO2025178973A1 (en) * | 2024-02-20 | 2025-08-28 | Iambic Therapeutics, Inc. | Solid state forms of her2 inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4062881A (en) | 1974-07-26 | 1977-12-13 | Cincinnati Milacron Chemicals, Inc. | Sulfide containing tin stabilizers |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9405355D0 (en) | 1994-03-18 | 1994-05-04 | Lucas Ind Plc | Vibrating element transducer |
| DE122005000053I2 (de) * | 1995-03-30 | 2008-01-17 | Pfizer Prod Inc | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| WO1997038973A1 (en) * | 1996-04-16 | 1997-10-23 | Ube Industries, Ltd. | Hydrazine compounds, process for the preparation thereof, and insecticides for agricultural and horticultural use |
| ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| TW533204B (en) * | 1998-07-30 | 2003-05-21 | Wyeth Corp | A process for preparing substituted quinazoline derivatives |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US6627634B2 (en) * | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| AU7307101A (en) | 2000-06-30 | 2002-01-14 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| WO2002034727A2 (en) | 2000-10-27 | 2002-05-02 | Novartis Ag | Treatment of gastrointestinal stromal tumors |
| DE10063435A1 (de) * | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EP1369418B1 (en) | 2001-02-21 | 2010-07-28 | Mitsubishi Tanabe Pharma Corporation | Quinazoline derivatives |
| TWI324597B (en) | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| WO2004006846A2 (en) * | 2002-07-15 | 2004-01-22 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| JP4353903B2 (ja) | 2005-01-07 | 2009-10-28 | 東京エレクトロン株式会社 | クラスタツールの処理システム |
| EP1883631A1 (en) | 2005-05-25 | 2008-02-06 | Wyeth | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof |
| EP1948179A1 (en) * | 2005-11-11 | 2008-07-30 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| CA2639936C (en) | 2006-01-26 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
| CN100345856C (zh) | 2006-03-10 | 2007-10-31 | 武汉化工学院 | 一种制备葡萄糖醛酸内酯的酯化及结晶工艺方法 |
| US8604044B2 (en) | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| AU2008233930A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CN101584696A (zh) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| CN105037333A (zh) | 2009-12-21 | 2015-11-11 | 张强 | 新的喹唑啉衍生物 |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN102382106A (zh) * | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| SG10201601711SA (en) | 2011-03-04 | 2016-04-28 | Newgen Therapeutics Inc | Alkyne Substituted Quinazoline Compound And Methods Of Use |
| CN102918029B (zh) * | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
-
2011
- 2011-05-17 CN CN201180023195.6A patent/CN102918029B/zh active Active
- 2011-05-17 WO PCT/CN2011/074165 patent/WO2012155339A1/zh not_active Ceased
-
2012
- 2012-05-16 TW TW101117362A patent/TWI448461B/zh active
- 2012-05-17 JP JP2014511560A patent/JP2014513731A/ja active Pending
- 2012-05-17 EP EP12786332.2A patent/EP2709999A4/en not_active Withdrawn
- 2012-05-17 TW TW101117618A patent/TWI555745B/zh active
- 2012-05-17 CA CA2873710A patent/CA2873710A1/en not_active Abandoned
- 2012-05-17 WO PCT/US2012/038458 patent/WO2012158979A1/en not_active Ceased
- 2012-05-17 US US14/118,200 patent/US9187459B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513731A5 (enExample) | ||
| JP6754864B2 (ja) | Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
| KR102318875B1 (ko) | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 | |
| TWI896726B (zh) | 一種ｅｇｆｒ抑制劑及其製備方法和應用 | |
| TWI662026B (zh) | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 | |
| TWI448461B (zh) | 4-aniline-6-butenamide-7-alkyl ether quinazoline derivatives, methods and uses thereof | |
| WO2022007841A1 (zh) | 一种egfr抑制剂、其制备方法和在药学上的应用 | |
| EA036453B1 (ru) | Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr | |
| KR20210043016A (ko) | 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법 | |
| CN105315285A (zh) | 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途 | |
| JP7660801B2 (ja) | 脳透過性ｂｔｋ又はｈｅｒ２阻害剤としての化合物およびその製造方法と応用 | |
| JP2020189852A (ja) | キナーゼ阻害活性を有するベンズヒドロール−ピラゾール誘導体及びその使用 | |
| CN103965174B (zh) | 含有锌结合基的喹唑啉基egfr酪氨酸激酶抑制剂 | |
| CN111196814B (zh) | 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用 | |
| CN103717590B (zh) | 喹唑啉-7-醚化合物及使用方法 | |
| WO2021129561A1 (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
| CN105461708A (zh) | 喹唑啉类酪氨酸激酶抑制剂及其制备和应用 | |
| CN104844526B (zh) | 一种4,6-嘧啶二胺类化合物及其制备方法和应用 | |
| WO2022194265A1 (zh) | 一种喹唑啉类化合物、组合物及其应用 | |
| JP2020524659A (ja) | 化合物 | |
| TWI847289B (zh) | 喹唑啉類化合物、組合物及其應用 | |
| CN118878515B (zh) | 一种取代苯胺嘧啶类化合物及其制备方法和用途 | |
| TWI820414B (zh) | 喹唑啉類化合物、製備方法及其應用 | |
| CN113493407B (zh) | 一种吡啶类化合物及其制法和药物用途 | |
| CN104163815B (zh) | 含吲哚的喹唑啉类化合物及其在治疗egfr依赖性肿瘤疾病中的用途 |